Endothelins are endothelial cell-derived peptides with potent vasoconstrictor properties. We investigated the actions of porcine/human endothelin-1 (ET-1) on the microvasculature of the guinea pig lung perfused at constant flow with Ringers-albumin. We measured the perfusion pressure, distribution of pulmonary vascular resistance (using the double occlusion method), lung weight change, and the pulmonary capillary filtration coefficient. At concentrations of >10-10 M, ET-1 produced dose-dependent increases in mean pulmonary artery pressure (EC50, -10-9 M), which were rapid in onset and biphasic (first phase peaking at 1-2 minutes; second phase peaking at 10-15 minutes) up to 60 minutes of the perfusion period. The vasoconstrictor response was sustained for the 60-minute perfusion period. The pulmonary vasoconstriction was inhibited by pretreatment with indomethacin (10`M), the thromboxane A2 receptor antagonist SQ-29,548 (4x 10-6 M), or papaverine (10-5 M). Nifedipine (10`or 10i M) had no effect on the first phase but prevented the second phase of the vasoconstriction. The vasoconstriction was primarily the result of a 10-fold increase in pulmonary venous resistance. Pulmonary edema developed after ET-1 challenge because of the venoconstriction and the resultant pulmonary capillary hypertension. However, the pulmonary capillary filtration coefflicient was unchanged, indicating that pulmonary vascular permeability did not increase.
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ET-1 also had no effect on transendothelial 1251-albumin flux. The results indicate that ET-1 is a potent thromboxane-dependent venoconstrictor in the guinea pig lung. ET-1 induces pulmonary edema because of its ability to increase pulmonary capillary hydrostatic pressure.
The mechanism of the sustained pulmonary venoconstriction may involve calcium mobilization via dihydropyridine-sensitive calcium channels. (Circulation Research 1991; 69:157-164) E ndothelins are endothelial-derived vasoconstrictor peptides isolated from medium conditioned by cultured endothelial cells.1-4 Endothelins are released in the circulation in the guinea pig lung in response to pulmonary vasoconstrictors such as thrombin.3 Studies indicate that the human/ porcine endothelin, ET-1, is a potent constrictor of coronary,4 renal,5,6 mesenteric,7 and other peripheral47-9 vessels. ET-1 also constricts airway8s10'1 and intestinal7 smooth muscle. Under conditions of increased basal vascular tone, ET-1 induces vasodilation in the rat mesentery7"2 and other peripheral vessels7 and in the pulmonary circulation.13 ET-1 is a peripheral vasodilator but a mild pulmonary vasoconstrictor in the anesthetized cat.'4 The pulmonary vasomotor actions of ET-1 and the mechanisms me-diating the alterations are not well understood. Because of endothelin's possible effect in increasing pulmonary capillary hydrostatic pressure and vascular permeability, ET-1 also may mediate pulmonary edema. In the present study, we used the guinea pig lung perfused at constant flow with Ringers-albumin to study the direct responses of ET-1 on pulmonary vasomotor tone and the roles of the cyclooxygenase pathway and extracellular calcium in mediating the pulmonary vasomotor responses.
Materials and Methods

Lung Perfusion
Thirty healthy male or female Hartley guinea pigs (Charles River Laboratories, Inc., Wilmington, Mass.) weighing 550±25 g (mean+SEM) were anesthetized with pentobarbital sodium (50 mg/kg i.p.; Abbott Laboratories, Chicago). The trachea was cannulated before the thorax was opened. Heparin sodium (700 units/kg) was administered by intracardiac injection, and the animals were bled by severing the abdominal aorta. The heart and lungs were removed carefully en bloc and suspended from one end of a beam balance. The lung perfusion system has been detailed elsewhere.15 Briefly, catheters were placed in the pulmonary artery and left atrium. The lungs were covered with plastic wrap to reduce evaporative water loss. Perfusion of the system using a peristaltic pump (model 1215, Harvard Apparatus, Millis, Mass.) was begun within 5 minutes of pneumothorax with bubble traps included in the perfusion circuit. The perfusate was a phosphate buffered Ringer's solution containing bovine albumin (0.5 g/100 ml) (fraction V, Sigma Chemical Co., St. Louis) and the following components (mM): NaCl 137, CaCI2 1.8, MgC12 1.05, KCl 2.68, NaHCO3 0.66, NaH2PO4 0.130, Na2HPO4 0.869, and dextrose 5.55; this solution was prebubbled with 95% 02-5% CO2. The perfusion rate was set at 28 ml/min (0.05 I/kg/ min) for all experiments. Recirculation of the perfusate was begun after the venous effluent was clear of visible blood. The final recirculating volume was 300 ml. The perfusate temperature was set at 37°C, and left atrial pressure was adjusted to 3 cm H20. Because flow and left atrial pressure were held constant, changes in pulmonary arterial pressure (Ppa) reflected changes in the pulmonary vascular resistance (PVR). The lungs initially were inflated three times to 20 cm H20 and then kept statically inflated throughout the experiment with 95% 02-5% CO2 at a pressure of 2 cm H2O, with intermittent short-term increases in airway pressure to 20 cm H20.
Endothelial Cell Monolayer
Endothelial cells were grown to confluency on polycarbonate microporous filters (0.8-gm pore diameter) (Nucleopore Corp., Pleasanton, Calif.) and mounted onto the base of plastic wells as described. 16 Bovine pulmonary microvessel endothelial cells were isolated and cultured according to the method of Folkman et al. 17 Briefly, subpleural lung tissue was minced, treated with collagenase, and filtered through 160-gm nylon mesh, and the suspension was centrifuged. The pellet was washed three times and resuspended in RPMI-1640, 20% heparinized fetal bovine serum (Sigma) with retinal-derived growth factor, then plated on fibronectin-coated culture dishes. Endothelial cell colonies obtained after several days of incubation were isolated with a glass cloning cylinder and replated onto other fibronectin-coated dishes. The cells obtained were identified as endothelial cells by their morphology, absence of factor VIII-related antigen, incorporation of acetylated low density lipoprotein, and activity of angiotensin-converting enzyme. Dulbecco PP, was elevated by raising the left atrial pressure for 5 minutes, and the Kfx was determined from the relation of rate of weight increase from minutes 2 through 5 when the increase in lung weight was assumed to be due to transvascular fluid filtration. 19 KfC was measured (n =7) after the addition of papaverine (0.4 mg/100 ml) (Sigma), which was used to paralyze the vasculature, thus abrogating any changes in vascular tone due to ET-1. In experiments using this protocol, papaverine independently did not alter the PVR, lung weight, or Kf,C values.'9 At the end of each experiment, the lungs were dissected free of nonpulmonary tissue, weighed, and dried to a constant weight at 500C.
In some experiments, left atrial effluent samples were collected and analyzed for thromboxane B2
(TXB2) and 6-ketoprostaglandin F2a (6-keto-PGF2a), the stable metabolites of thromboxane A2 and prostacyclin, respectively, using a double-antibody radioimmunoassay. 20 The effect of ET-1 on endothelial monolayer permeability was determined using the permeability system described above.'6 Briefly, the luminal wells (0.7-mI capacity), which consisted of the plastic cylinders with polycarbonate filters on which endothelial cells were grown, were suspended in larger abluminal compartments (25-ml capacity), the contents of which were stirred constantly and maintained at 370C. Both compartments were filled with Hanks' balanced salt solution (GIBCO) containing 0.5% bovine serum albumin (Sigma). ( Figure 1 ). Because the lungs were perfused at constant flow, the changes in Ppa directly reflect changes in PVR. PAF produced a greater increase in pulmonary vasomotor tone on a molar basis than ET-1 ( Figure 1 ). The other points for Figure 1 are from previously obtained values in this laboratory using the same guinea pig preparation. ET-1 was a more potent pulmonary vasoconstrictor on a molar basis than substance p,23 a-thrombin,20 and arachidonic acid19 (Figure 1 ). The addition of 10-9 M ET-1 produced biphasic increases in the pulmonary vasomotor tone ( Figure  2 ). The increase occurring within 1-2 minutes after ET-1 challenge was threefold above baseline, followed by a decrease over the next 5 minutes and then a secondary increase of threefold above baseline 15 minutes after ET-1 challenge. Pulmonary vasomotor tone gradually returned toward baseline but remained 70% above baseline even at the end of the 60-minute study period. Figure 3 shows the time course of the pulmonary vasoconstrictor response and the concomitant increase in lung weight in response to 10-9 M ET-1. The pulmonary vasoconstriction was biphasic ( Figure  3B ). The vasoconstriction was associated with a transient initial decrease in lung weight within 15 seconds, followed by a sharp increase within 1 minute and then a progressive increase over the next 16 minutes ( Figure 3A) . After this period, lung weight stabilized. Addition of a higher concentration of ET-1 (10`8 M) led to the rapid development of massive pulmonary edema within 20-30 minutes of the ET-1 administration; therefore, the time course studies were made using 10-9 M ET-1. Figure 4 shows the effect of ET-1 on the pulmonary venous effluent TXB2 concentrations. A was associated with a secondary rise in PVR), and then it decreased toward baseline levels by 30 minutes, when PVR also decreased (although both TXB2 and PVR were elevated above baseline at this time). The increase in 6-keto-PGF2a was significantly less (p<0.05) than the increase in TXB2 (from 0.6±0. 4 ng/ml at baseline to 1.2±+0.5 ng/ml at 5 minutes), and this level was maintained for the study period. Indomethacin inhibited TXB2 (Figure 4 PP, increased in parallel with the development of pulmonary vasoconstriction after ET-1 ( Papaverine (10-5 M) also prevented the ET-1-induced increases in Rpa, Rpv, and Pp.
ET-1 resulted in a 48% increase in lung wet weight over the first 15 minutes, followed by its stabilization for the 60-minute perfusion period ( Figure 6 ). Ppc decreased toward baseline after 15 minutes, whereas lung weight continued to be elevated. Indomethacin, SQ-29,548, papaverine, and nifedipine prevented the development of pulmonary edema ( Figure 6 ); this effect of nifedipine was observed at both concentrations of 10-5 and 10`7 M.
The Kf,C value was unchanged from baseline values after the administration of ET-1 (0.092+0.016, 0.075±+0.011, 0.075+0.018, and 0.142±0.086 ml/ min/cm H2O/g dry wt at baseline, 15, 30, and 45 minutes, respectively). ET-1 (10-9 to 10-75 M) also had no effect on the transendothelial 1251-albumin clearance rates (Figure 7) , whereas a-thrombin increased the "'I-albumin clearance (from baseline value of 0.150±0.20 to 0.355±0.15 ,ul/min after thrombin).
Discussion
In the present study, we have demonstrated that ET-1 challenge of guinea pig lungs perfused with Ringers-albumin causes pulmonary vasoconstriction. The response was potent and concentration dependent, with a threshold ET-1 concentration of 10`10 M. The ET-1-mediated pulmonary vasoconstriction response was biphasic, with the initial rise in PVR peaking at 1 minute followed by a secondary increase peaking at 15 minutes. The increase in PVR was associated with thromboxane generation, because TXB2, the primary metabolite of thromboxane, was released in the lung effluent after ET-1 challenge. In contrast, the increase in the effluent prostacyclin concentration was small. Thromboxane appears to be a critical mediator of the response, because pulmonary vasoconstriction was inhibited by the cyclooxygenase inhibitor indomethacin, as well as by the thromboxane receptor antagonist SQ-29,548. We cannot exclude the possibility that other arachidonic metabolites also are involved, because prostaglandin D2 and prostaglandin F2 bind to the thromboxane receptor2124 and thereby may mediate pulmonary vasoconstriction. ET-1 is known to activate phospholipase A2 in vascular smooth muscle cells,25 and hence it may directly induce the release of arachidonic acid metabolites in lung tissue.7 Because the generation of thromboxane and the rise in PVR were sustained, the results suggest a persistent activation of phospholipase A2.
The pulmonary vasoconstrictor response to ET-1 in the guinea pig lung is quite different from the pulmonary vasodilation observed in other studies.13 ET-1-induced pulmonary vasodilation appears to be dependent on the basal pulmonary vasomotor tone; that is, dilation occurred in response to ET-1 in lungs with high tone, such as in the neonatal pulmonary circuit. 26 The mechanisms of this effect are not clear, although cyclooxygenase-derived arachidonic acid metabolites do not appear to be involved,26 as is the case with ET-1-induced pulmonary vasoconstriction in the adult guinea pig lung.
The pulmonary vasoconstriction induced by ET-1 was long-lived, lasting the 60-minute duration of the perfusion period. This observation is consistent with other studies in which ET-1 had no effect on permeability to dextran in the hamster cheek pouch microvessels.37
In conclusion, the pulmonary venoconstrictor response to ET-1 in the guinea pig lung is biphasic. Thromboxane generation induced by ET-1 appears to be a critical signaling event responsible for the pulmonary venoconstriction. Calcium influx mediated by dihydropyridine-type calcium channels may be involved in the venoconstriction, because this response was inhibited by nifedipine. ET-1 also caused pulmonary edema as a result of the rise in pulmonary capillary hydrostatic pressure. In view of the potent and long-lived pulmonary venoconstriction and edematogenic effects of ET-1, it is reasonable to assume that ET-1 release in situ will have profound effects in the pathogenesis of acute lung injury and other related disorders.
